We used Durvalumab, an IgG1T monoclonal antibody to PD-L1 approved by the FDA for previously treated patients with advanced bladder cancer immunotherapy in 2017, to block PD1/PD-L1 signaling in each animal PDX model. This evidence concerns the gene CD274 and urinary bladder cancer.